APA

Neri B., Doni L., Gemelli M. T., Fulignati C., Turrini M., Di Cello V., Dominici A., Maleci M., Mottola A., Ponchietti R., Raugei A., Valsuani G. & Cini G. (20020918). Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer. : The Journal of urology.

Chicago

Neri B, Doni L, Gemelli M T, Fulignati C, Turrini M, Di Cello V, Dominici A, Maleci M, Mottola A, Ponchietti R, Raugei A, Valsuani G and Cini G. 20020918. Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer. : The Journal of urology.

Harvard

Neri B., Doni L., Gemelli M. T., Fulignati C., Turrini M., Di Cello V., Dominici A., Maleci M., Mottola A., Ponchietti R., Raugei A., Valsuani G. and Cini G. (20020918). Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer. : The Journal of urology.

MLA

Neri B, Doni L, Gemelli M T, Fulignati C, Turrini M, Di Cello V, Dominici A, Maleci M, Mottola A, Ponchietti R, Raugei A, Valsuani G and Cini G. Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer. : The Journal of urology. 20020918.